Clinical Trial

Fetuin A as a Predictor of Deterioration of Renal Function in Hypertonic Patients

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 27, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Commonly used parameters (creatinine, estimated glomerular filtration rate, and urine albumin/creatinine ratio) for prediction of decline of renal function are sensitive for advanced kidney impairment. Modified human urine Fetuin A (urine Fetuin A) with specific modification in urine (Fetuin A) can earlier predict the progression of kidney disease in patients with diabetes. Studies evaluating urine Fetuin A in hypertonic patients are still lacking.
Trial Details
NCT Number NCT05963126
Lead Sponsor University Hospital Ostrava
Conditions Arterial Hypertension
Enrollment 200 participants
Start Date 2023-07-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-07-27